特集 : 国別レポートが13,000件から検索可能になりました!

特集 : 海外市場の委託調査がセミカスタムベースでお手軽にできます

株式会社グローバルインフォメーション
表紙
市場調査レポート
商品コード
390830

世界の体外診断(IVD)市場:技術、製品、ユーザビリティ、用途、エンドユーザー、地域別 - 成長、動向、予測

In-Vitro Diagnostic Market - Growth, Trends, and Forecasts (2020 - 2025)

出版日: | 発行: Mordor Intelligence LLP | ページ情報: 英文 115 Pages | 納期: 2-3営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=105.49円
世界の体外診断(IVD)市場:技術、製品、ユーザビリティ、用途、エンドユーザー、地域別 - 成長、動向、予測
出版日: 2020年08月01日
発行: Mordor Intelligence LLP
ページ情報: 英文 115 Pages
納期: 2-3営業日
担当者のコメント
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

体外診断(IVD)は、多様な生体試料を用いて健康状態の診断をするものです。世界の体外診断(IVD)市場は、調査期間の2018年から2023年にかけて5.5%のCAGRで推移することが予測されています。

当レポートでは、世界の体外診断(IVD)市場について調査し、市場の概要、技術・製品・ユーザビリティ・用途・エンドユーザー・地域別の市場動向、市場規模の推移と予測、成長要因・阻害要因ならびに市場機会・課題の分析、競合情勢、主要企業のプロファイルなど、体系的な情報を提供しています。

目次

第1章 イントロダクション

  • 市場の定義

第2章 調査方法

第3章 エグゼクティブサマリー

第4章 主な影響要因

第5章 市場の概要

  • 現在の市場シナリオ
  • ファイブフォース分析
    • 買い手の交渉力
    • 供給企業の交渉力
    • 新規参入業者の脅威
    • 代替品の脅威
    • 競争企業間の敵対関係

第6章 成長要因、阻害要因、市場機会、課題の分析(DROC)

  • 成長要因
    • 慢性疾患および感染性疾患の高い罹患率
    • POC診断の利用の増加
    • 先進技術
    • 私立病院および独立検査機関の増加
  • 阻害要因
    • 厳格な規制
    • 煩雑な償還手続き
    • 開発途上国の病院や研究所の限られた予算
  • 市場機会
  • 主な課題

第7章 世界の体外診断(IVD)市場:セグメント別

  • 技術別
    • 免疫化学
    • POC診断
    • 分子診断
    • 血液学
    • 組織診断
    • 微生物学
    • 血糖自己測定
    • その他
  • 製品別
    • 機器
    • 試薬
    • データ管理システム
  • ユーザビリティ別
    • 使い捨て
    • 再利用可能
  • 用途別
    • 感染症
    • 糖尿病
    • がん/腫瘍学
    • 心臓病学
    • 自己免疫疾患
    • 腎臓病
    • 薬物検査
    • HIV/AIDS
    • その他
  • エンドユーザー別
    • 研究所
    • 病院
    • 学術機関
    • POC検査
    • その他
  • 地域別
    • 北米
    • 欧州
    • アジア太平洋
    • 中東・アフリカ
    • 南米

第8章 競合情勢

  • 合併・買収分析
  • 合意・提携・協力
  • 新製品の発売

第9章 主要企業のプロファイル

  • Biomerieux
  • Danaher Corporation
  • Roche Diagnostics
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories, Inc.
  • Abbott Laboratories
  • Bayer AG
  • Arkray, Inc.
  • Sysmex Corporation
  • Johnson & Johnson
  • Siemens AG

第10章 市場の将来展望

目次
Product Code: 49602

Global In-Vitro Diagnostic market is expected to grow with a CAGR of 4.81% over the forecast period. The growth of the global IVD market can be attributed to the high prevalence of chronic and infectious diseases. Chronic diseases are a growing global challenge, and according to WHO estimates, account for approximately 60% of all deaths, worldwide. The current market is also growing due to the use of advanced technologies in the IVD market. There has been a paradigm shift from traditional diagnostics to a new generation diagnostics that work at the gene level. This was made possible by the inclusion of advanced technologies, such as genetic testing, molecular diagnostics, polymerase chain reaction (PCR) and next-generation sequencing (NGS).

Key Market Trends

Reagents are Expected to hold Largest Market Share in the Product Segment

In the product segment of the In-Vitro Diagnostic market, the reagent is believed to have the largest market size and is expected to witness a CAGR of 4.8% in the forecast period.

The reagent segment of the market studied includes chemical, biological, or immunological components, solutions, or preparations intended by the manufacturer to be used during the in-vitro diagnosis process. Given the high cost of many diagnostic platforms, it is common for manufacturers to lease equipment instead of selling technology outright to end users. In these arrangements, the lease is tied to contracts to purchase associated reagents or assays for the equipment over the life of the contract. Many diagnostic companies have in excess of 75% of sales from consumables such as assays and reagents, and such agreements guarantee the generation of cyclic revenues associated with the sale of reagents and other consumables.

Many developing countries have established local immunoassay reagent programs to manufacture low-cost, high-quality immunoassay reagents. Kits from these projects are now beginning to become available and are likely to fuel the market expansion.

North America Dominates the Market and is Expected to continue its Dominance in the Forecast Period

North America currently dominates the market for In-Vitro Diagnostic and is expected to continue its stronghold for a few more years. This region is expected to increase its market share in the future owing to the well-established healthcare industry and rising prevalence of the chronic diseases in the region. The United States holds the majority of the market in the North America region; this is due to the rising healthcare expenditure, along with rapid adoption of point-of-care testing.

Competitive Landscape

The In-Vitro Diagnostic market is highly competitive and consists of several major players. In terms of market share, few of the major players currently dominate the market. However, with technological advancement and product innovation, mid-size to smaller companies are increasing their market presence by introducing new products at lesser prices. Companies like Thermo Fischer Scientific Inc., Abbott Laboratories, Siemens Healthcare GmbH and F. Hoffmann-La Roche AG. holds the substantial market share in the In-Vitro Diagnostic market.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 High Prevalence of Chronic Diseases
    • 4.2.2 Increasing Use of Point-of-care (POC) Diagnostics
    • 4.2.3 Advanced Technologies in In-vitro Diagnostic Products
    • 4.2.4 Increasing Awareness and Acceptance of Personalized Medicine and Companion Diagnostics
  • 4.3 Market Restraints
    • 4.3.1 Stringent Regulations Regarding Product Approvals
    • 4.3.2 Cumbersome Reimbursement Procedures
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Test Type
    • 5.1.1 Clinical Chemistry
    • 5.1.2 Molecular Diagnostics
    • 5.1.3 Immuno Diagnostics
    • 5.1.4 Haematology
    • 5.1.5 Other Types
  • 5.2 By Product
    • 5.2.1 Instruments
    • 5.2.2 Reagents
    • 5.2.3 Other Products
  • 5.3 By Usability
    • 5.3.1 Disposable IVD Devices
    • 5.3.2 Reusable IVD Devices
  • 5.4 By Application
    • 5.4.1 Infectious Disease
    • 5.4.2 Diabetes
    • 5.4.3 Cancer/Oncology
    • 5.4.4 Cardiology
    • 5.4.5 Autoimmune Disease
    • 5.4.6 Nephrology
    • 5.4.7 Other Applications
  • 5.5 By End Users
    • 5.5.1 Diagnostic Laboratories
    • 5.5.2 Hospitals & Clinics
    • 5.5.3 Other End Users
  • 5.6 Geography
    • 5.6.1 North America
      • 5.6.1.1 United States
      • 5.6.1.2 Canada
      • 5.6.1.3 Mexico
    • 5.6.2 Europe
      • 5.6.2.1 Germany
      • 5.6.2.2 United Kingdom
      • 5.6.2.3 France
      • 5.6.2.4 Italy
      • 5.6.2.5 Spain
      • 5.6.2.6 Rest of Europe
    • 5.6.3 Asia-Pacific
      • 5.6.3.1 China
      • 5.6.3.2 Japan
      • 5.6.3.3 India
      • 5.6.3.4 Australia
      • 5.6.3.5 South Korea
      • 5.6.3.6 Rest of Asia-Pacific
    • 5.6.4 Middle-East and Africa
      • 5.6.4.1 GCC
      • 5.6.4.2 South Africa
      • 5.6.4.3 Rest of Middle-East and Africa
    • 5.6.5 South America
      • 5.6.5.1 Brazil
      • 5.6.5.2 Argentina
      • 5.6.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 BioMerieux SA
    • 6.1.2 Danaher Corporation
    • 6.1.3 F. Hoffmann-La Roche Ltd
    • 6.1.4 Becton, Dickinson and Company
    • 6.1.5 Bio-Rad Laboratories, Inc.
    • 6.1.6 Abbott Laboratories
    • 6.1.7 Arkray Inc.
    • 6.1.8 Sysmex Corporation
    • 6.1.9 Ortho Clinical Diagnostics
    • 6.1.10 Siemens Healthcare GmbH
    • 6.1.11 Thermo Fischer Scientific Inc

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

株式会社グローバルインフォメーション
© Copyright 1996-2020, Global Information, Inc. All rights reserved.